Podcasts about early development

Episode 321: Understanding Baby Milestones: A Pediatric PT's Guide to Early Development with Dr. Allison Mell, PT, DPTThis week on the Untethered Podcast, Hallie welcomes Dr. Allison Mell, a pediatric physical therapist with a deep passion for child development. Allison shares her journey from general physical therapy to specializing in infant development, focusing on empowering parents with the tools and knowledge to support their child's growth. The conversation dives into essential early milestones such as tummy time, rolling, crawling, and walking, emphasizing the quality of movement over just meeting checklists. The episode also tackles the recent removal of certain milestones from the CDC guidelines and the implications for early intervention and parental confidence. If this episode has resonated with you in some way, take a screenshot of you listening, post it to your Instagram Stories, and tag Hallie @halliebulkinIn this episode, you'll hear:Allison's transition into pediatric physical therapy and her mission to support families.The importance of recognizing and supporting quality of movement in early development.Tummy time as a foundational activity for motor skills and strength building.Practical, everyday strategies for encouraging movement and milestones at home.Discussion on rolling and how it can impact sleep and comfort.The effects of CDC milestone changes on early detection and intervention.Barriers parents face when seeking developmental evaluations and services.Encouragement for parents to trust their instincts and advocate for their child's needs.Whether you're a parent, provider, or simply passionate about early childhood development, this episode is packed with valuable insights and support!LINKSGet to know Dr. Allison on Instagram. Check out her website: https://www.totsontarget.com/Be part of our Myo Fam! Join us inside The Myo Membership: www.themyomembership.comBecome a Certified Myofunctional Therapist™ (CMT®). Enroll here: www.themyomethod.comReady to turn your "myo eyes" on? Join our webinar: https://www.feedthepeds.com/myo-webinarDownload a Free F.A.S.T. Myo Screening Packet Here: FastMyoScreening.comFind a myofunctional therapist: www.themyodirectory.comConnect with Hallie on Instagram, Facebook & LinkedINHaven't left a review yet? Click here and thank you, as always, for being a listener!Want to watch more of the episode? Click here Hosted on Acast. See acast.com/privacy for more information.

In this newscast: The local advocates who filed a petition with the City and Borough of Juneau last month to put harder limits on cruise ship tourism have withdrawn it; The Juneau Assembly passed an ordinance mandating the Juneau Police Department release body-word camera footage no more than 30 days after a city police officer shoots someone; Another Ketchikan school board member stepped down, following the district's board president, superintendent and another board member; It's still not clear why the Alaska Department of Education and Early Development failed a federal test that saves the state millions of dollars; Juneau residents held a tree-planting ceremony in honor of Arbor Day yesterday.

In this newscast: The Juneau School District Board of Education appointed Steve Whitney to the board on Saturday; Senator Lisa Murkowski has introduced a bill that would reauthorize funds for landslide monitoring projects across Southeast Alaska; The Alaska Department of Education and Early Development failed a test that allows it to include millions of federal dollars towards its contributions to education funding; Tribal leaders from across the country spoke out last week at a U.S. Senate hearing against changes within the Department of Health and Human Services; Curious Juneau: What's the story behind the Fiddlehead Cookbook's North Douglas chocolate cake?

In this newscast: A German Shepherd who was on the lam for nearly three months has been captured to returned to her family; The Alaska Department of Environmental Conservation says 400,000 gallons of process water spilled at a large lead and zinc mine in Northern Alaska yesterday; The Alaska Department of Education and Early Development is considering whether to reduce the amount of money local governments can give to school district, but a new bill would allow local governments to continue to fund school districts as they have been; Juneau's city-owned ski area expects to run a deficit for the foreseeable future, and their plan to dig out of the deficit relies heavily on revenue from a gondola that has yet to be built; Lawmakers rejected two of Gov. Mike Dunleavy's nominees for state boards and commissions in a joint session of the state House and Senate yesterday

Mitch Bach sat down with João Perre Viana, the founder of Walking Mentorship, to talk one thing we tour operators are all familiar with: walking.But not many of us design week-long trips where all you do is walk. Sometimes alone. Sometimes in a group. That's it. Beyond some shared meals and moments, there isn't much of a plan. Each group takes on a different spirit, but it's all guided by a mentor who along the way tries to facilitate and gently foster personal transformation. What that looks like is up to the individual guest.This conversation veered away from the nitty-gritty of business, and towards diving into the importance and magic of what we do as experience creators.For more show notes, visit tourpreneur.com. And be sure to join nearly 20,000 tour operators in our Facebook group!1. Introduction to Walking Mentorship [00:00:09]Joao's background and origins in PortugalIs Walking Mentorship a tour company?2. Joao's Personal Journey and Spark for Walking Mentorship [00:01:16]The first Camino de Santiago in 1993The impact of the walk and self-discoveryRealization of a calling to this work3. Founding and Early Development of Walking Mentorship [00:04:23]Corporate career delay and returning to the ideaEmail to “fools, friends, and family,” and pilot programsEarly feedback and attempts to give up on the idea4. The Nature of Walking Journeys as Transformational Experiences [00:07:14]Layers of experience: curiosity, physicality, purpose, self-understanding, spirituality, cultureDoors in a room analogy for guiding participant journeys5. Participant Freedom, Responsibility, and Structure [00:12:06]Emphasis on total freedom and responsibilityRare participant withdrawal and the ethos behind the program6. Difference Between Typical Travel and Mentorship Walking Journeys [00:13:10]Critique of traditional, structured, checklist-driven toursDeprogramming guests and creating space for transformation7. Risk, Challenge, and Your Personal “Everest” [00:17:26]Meaning of risk (internal vs. external threats)The “wolves” participants face within themselvesEnsuring physical and psychological safety8. Common Motivations and Unique Outcomes [00:19:55]The universal quest or search among participantsEvery individual's unique journey and needs“There is no replay” principle9. The Mentorship Structure and Methodology [00:22:20]Mentor's responsibilities and boundariesPreparing participants for returning homeStructured support with eventual independence10. Designing for Difficulty and Personal Growth [00:26:53]Backpack packing as a life metaphorBalancing physical challenge with adaptabilityReading the group and tailoring the journey11. Practical Aspects and Device Usage [00:32:22]Approach to phone/device use on programsFostering mindful interaction with technology12. Lessons for Day Tour Operators and Short-Form Experiences [00:35:16]Applying listening, eye contact, and personalization even to short toursOffering small but impactful experiences13. The Art of Listening and Asking Questions [00:40:04]Listening as a crucial guiding skillAsking questions through...

In this newscast: The federal government may soon return a traditional subsistence site connected to Douglas Island to its original tribal owners; The next season of the PBS KIDS show “Molly of Denali” will be the last for the foreseeable future. The team behind the award-winning children's TV show will stop working on new content. Molly of Denali is widely celebrated in Alaska because it features an Alaska Native lead character and showcases Alaska Native culture; The Alaska Department of Education and Early Development is considering whether to reduce the amount of money local governments can give to school districts. A new bill in front of state lawmakers would allow local governments to continue to fund school districts as they have been; State prosecutors say two Anchorage police officers were legally justified in the fatal shooting of a man in February who police say had barricaded himself in a Midtown hotel and threatened a woman and her four children.

Send us a textDr. Martin Brenner, DVM, Ph.D. is Chief Executive Officer and Chief Scientific Officer of iBio ( https://ibioinc.com/team/martin-brenner-dvm-ph-d/ ), a biotech company developing the next generation of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function, as well as a pipeline of therapeutic candidates in immuno-oncology for some of the most-difficult-to-treat cancers, including solid tumors in lung, colorectal, and breast cancer, head and neck cancer, pancreatic cancer and glioblastoma, a fast-growing brain tumor. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, Dr. Brenner was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, Dr. Brenner was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team's research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.Dr. Brenner has a DVM, Veterinary Medicine, Ludwig-Maximilians-Universität München and a Ph.D., Pharmacology  Tieraerztliche Hochschule Hannover.#MartinBrenner #iBio #Cardiometabolic #Obesity #Medicines #WeightLoss #MetabolicHealth #ImmunoOncology #GLP1 #BispecificAntibodies #ArtificialIntelligence #TransformingGrowthFactorBeta #Myostatin #ActivinA #ActivinE #MuscleMass #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Guest: Nadia Lubowski | Director of The Anton Lubowski Educational Trust (ALET) Only 3 in 10 poor children are developmentally on track! Minister Siviwe Gwarube sounds the alarm on South Africa’s ECD crisis. Africa Melane speaks to Nadia Lubowski the Director of the Anton Lubowski Educational Trust on bridging the gap and ensuring every child gets the quality early learning they deserve.See omnystudio.com/listener for privacy information.

Send us a textDr. Rose Loughlin, Ph.D. is Executive Vice President, Research at Moderna ( https://www.modernatx.com/en-US ), a biotech company harnessing the power of mRNA technology to develop a new class of medicine for a range of unmet medical needs.Dr. Loughlin leads the company's platform science and therapeutics research organization, focusing on pioneering scientific advancements and further strengthening the Moderna's innovative pipeline.Dr. Loughlin previously served as Senior Vice President of Research and Early Development at Moderna, where she played a crucial role in advancing the Company's portfolio and platform strategy since joining in 2016. Before joining Moderna, Dr. Loughlin held roles at Biogen in business development and at L.E.K. Consulting, where she contributed to defining corporate and portfolio growth strategies for biopharmaceutical companies.Dr. Loughlin holds a Ph.D. in Biophysics from the University of California, Berkeley, and a Bachelor of Arts in physics from Harvard University, and did post-doc work in Germany at European Molecular Biology Laboratory.#RoseLoughlin #Moderna #mRNA #MessengerRNA #CancerVaccines #NeoantigenTherapy #Melanoma #RareDisease #IntercellularTherapeutics #PropionicAcidemia #MethylmalonicAcidemia #CMV #Cytomegalovirus  #EpsteinBarrVirus #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Want the secrets to building a resilient business and learn how to future-proof your entrepreneurial journey with insights from our guest, Phil Portman. Listen as Phil shares his inspiring transformation from a difficult upbringing to becoming a successful entrepreneur, motivated by the desire to secure a stable future for his autistic son. Discover the importance of moving from micromanaging to empowering your team and creating systems that ensure your business can thrive independently, even in your unexpected absence. Phil's personal anecdotes shed light on crucial strategies, including estate planning and key person life insurance, that safeguard your business legacy. Stay ahead of the curve in communication technology with our exploration of the rising trend of text messaging in the U.S., particularly among those under 50. Phil and I discuss the immediacy and convenience of text messaging in urgent scenarios, illustrated by personal stories. We also tackle the challenges posed by spam and phishing, unveiling how the industry, alongside Phil's company Textdrip, is innovating solutions like delivery tracking and spam prevention. This episode is a compelling blend of business wisdom and tech insights, designed to equip you with the knowledge to both secure your business operations and enhance your communication strategies.   Timestamps 00:00:00 - Introduction and Welcome to Business Legacy Podcast 00:00:37 - Phil Portman's Early Life and Motivation for Entrepreneurship 00:02:15 - Transition from Micromanaging to Empowering the Team 00:04:00 - The Importance of Estate Planning and Key Person Life Insurance 00:05:30 - Personal Anecdote: Business Associate's Health Crisis and Lessons Learned 00:07:00 - Strategies for Operational Resilience and Testing Systems 00:09:00 - Introduction to Text Messaging as a Preferred Communication Method 00:10:15 - Personal Experiences with the Convenience of Text Messaging 00:11:30 - Industry Challenges: Spam and Phishing in Text Messaging 00:12:51 - Textdrip's Innovative Solutions for Delivery Tracking and Spam Prevention 00:15:00 - Early Development and Challenges in Creating Textdrip 00:17:00 - Success in Targeting the Insurance Industry with Textdrip 00:18:45 - Advantages of Text Messaging Over Traditional Communication Methods 00:20:15 - Threats and Solutions for Future Text Messaging Security 00:22:30 - Ensuring High Deliverability and Accurate Reporting with Textdrip 00:24:00 - Case Study: Overwhelming Success of a Text Campaign 00:26:00 - The Importance of Personalized Customer Service at Textdrip 00:27:30 - Closing Remarks and Information on Trying Textdrip and Following Phil Portman   Episode Resources: Check out what Phil is up to at Textdrip here: https://textdrip.com/ Legacy Podcast: For more information about the Legacy Podcast and its co-hosts, visit businesslegacypodcast.com. Leave a Review: If you enjoyed the episode, leave a review and rating on your preferred podcast platform. For more information: Visit businesslegacypodcast.com to access the shownotes and additional resources on the episode.

Today, Frank Turek gives his best evidence against evolution. And he doesn't do well.Cards:Either God is Evil, or Doesn't Exist:https://www.youtube.com/watch?v=0g7Rl6zJbfYOriginal Video: https://tinyurl.com/2ybykceySources:Long-Term Follow-Up of Transsexual Persons Undergoing Sex Reassignment Surgery: Cohort Study in Sweden: https://tinyurl.com/ych994aeSection 5: Evolution, Climate Change and Other Issues: https://tinyurl.com/2lcvkhbzUnderstanding the Universality of the Genetic Code – Exploring the Biological Foundations of Genetic Diversity and Evolution: https://tinyurl.com/25hsd9tnUnderstanding COVID-19 mRNA Vaccines: https://tinyurl.com/22lhmlklTypes of Mutations: https://tinyurl.com/2ckj7aowThe Cambrian “Explosion”, Transitional Forms, and the Tree of Life: https://tinyurl.com/25mpphs2Dynamics of Dark-Fly Genome Under Environmental Selections: https://tinyurl.com/2c7kzlugGolden Rice FAQs: https://tinyurl.com/2yqol7ruAn operational definition of epigenetics: https://tinyurl.com/2a22fejuEpigenetics and Early Development: https://tinyurl.com/24ovcwotHow does epigenetics influence the course of evolution?: https://tinyurl.com/2yr9mo72Become a supporter of this podcast: https://www.spreaker.com/podcast/viced-rhino-the-podcast--4623273/support.

In this newscast: Alaska Supreme Court Chief Justice Susan Carney defended the court system's work and laid out plans for the future in a speech to state lawmakers; Juneau's Visitor Industry Director Alix Pierce shared data from an annual tourism survey that shows the conversation about the future of tourism's growth is far from over; An education compact is an agreement between tribal and state governments that allows tribes to run their own public schools, and Alaska's Department of Education and Early Development is working with tribes to kick start a compacting program and give tribes sovereignty over education; Alaska State Troopers arrested a Metlakatla man last week on six felony charges of sexual abuse of a minor, and they believe he may have had other victims

Send Kevin a Text MessageIn this episode of Don't Kill the Messenger, host Kevin Goetz sits down with Elizabeth Gabler, known for transforming literary works into cinematic successes. From her early days as an agent's assistant to becoming president of Fox 2000 and now Sony 3000 Pictures, Gabler shares insights from her remarkable career developing hit films like Life of Pi, The Devil Wears Prada, Mrs. Doubtfire, Marley and Me, and Where the Crawdads Sing.Early Career and Love of Reading (01:43)Gabler discusses her background in English literature and unexpected entry into entertainment, influenced by her early love of reading and her mother's influence as a librarian.United Artists and Early Development (10:12)The conversation explores her time at United Artists, working with industry legends like Jerry Weintraub and Billy Wilder, and developing projects like Roadhouse and Presumed Innocent that would later become successful films.Mrs. Doubtfire Development (13:30)Gabler shares the fascinating story of bringing Mrs. Doubtfire to the screen, including working with Robin Williams and director Chris Columbus, and overcoming initial skepticism about the project.Cast Away and Production Innovation (23:22)Discussion of the unique production process of Cast Away, including Tom Hanks' physical transformation and Robert Zemeckis making an entire other film during the production break.Life of Pi Journey (29:43)Elizabeth offers a detailed look at the challenging journey to bring Life of Pi to the screen, including Ang Lee's involvement and the innovative technical approaches required.Devil Wears Prada Casting (36:48)The pair discuss the casting process for The Devil Wears Prada, including securing Meryl Streep and Anne Hathaway, and the discovery of Emily Blunt.Current Projects and Personal Life (46:20)Gabler discusses her current project Klara and the Sun with director Taika Waititi and stars Jenna Ortega and Amy Adams, while also touching on personal aspects including the recent loss of her husband Lee.This intimate conversation reveals not just the mechanics of bringing books to screen, but the passion, persistence, and vision required to create lasting cinema. Gabler's deep love for storytelling and family themes runs throughout her work and this discussion, offering insights into how personal values can shape professional success.If you enjoyed this episode, please leave us a review or connect on social media. We look forward to bringing you more revelations from behind-the-scenes next time on Don't Kill the Messenger!Host: Kevin GoetzGuest: Elizabeth GablerProducer: Kari CampanoWriters: Kevin Goetz, Darlene Hayman, and Kari CampanoAudio Engineer: Gary Forbes (DG Entertainment) For more information about Elizabeth Gabler:Variety: https://variety.com/exec/elizabeth-gabler/IMDB: https://www.imdb.com/name/nm1992894/LinkedIn: https://www.linkedin.com/in/elizabeth-gabler-7b030a19 For more information about Kevin Goetz:Website: www.KevinGoetz360.comAudienceology Book: https://www.simonandschuster.com/books/Audience-ology/Kevin-Goetz/9781982186678Facebook, Twitter, Instagram: @KevinGoetz360Linked In @Kevin Goetz

What makes a great sports program and how can parents and booster clubs elevate the experience for everyone involved? Jenny Richardson, head coach of the Georgetown Lady Eagles Volleyball team, shares her journey of leading her team to the state semifinals. With 16 years of coaching experience, Jenny's expertise in fostering talent, community support, and teamwork sets her apart. Jenny highlights the importance of community involvement, early player development, and the irreplaceable role of a dedicated booster club. From hosting volleyball clinics for young athletes to maintaining strong relationships with middle school coaches, Jenny reveals strategies to build cohesive and goal-driven teams. Tune in to learn how creating a supportive, hard-working community can lead to sustained success in sports.    Key Takeaways:   (00:02) - Meet Jenny Richardson: Georgetown Lady Eagles Volleyball Coach (01:05) - The Importance of Community Support (01:59) -  Building a Successful Sports Program (03:33) -  Early Development and Coaching Strategies (05:02) -  2024 Season Highlights and Team Dynamics (06:40) -  Assistant Coach's Unique Perspective (08:16) - The Role of the Booster Club (13:34) -  Sun City Boosters: A Unique Support System (16:40) -  Rebuilding for the Future (18:25) -  Advice for Coaches and Booster Volunteers (22:56) -  Jenny's High School Experience and Lifelong Friendships   Resources: https://ghs.georgetownisd.org/departments/athletics/athletics-home/ghs-volleyball/coach-jenny-richardson  

On today's Midday Report with Host Terry Haines: The Alaska Board of Education and Early Development released a draft statewide cell phone policy for students. Gov. Mike Dunleavy on Wednesday praised a series of executive orders President Donald Trump issued shortly after taking office. And powerful winter storm systems are set to impact most of western, northern and interior Alaska from Thursday evening through the weekend. Photo: President Donald Trump signs an executive order at the White House supporting natural resource development in Alaska on Monday, Jan. 21, 2025 in Washington. (CSPAN)

How do we find the right dose in immune-oncology trials? Is the traditional “maximum tolerated dose” approach still enough, or should we also focus on efficacy? In this episode of The Effective Statistician, I talk with Teppo Huttunen, a seasoned statistician and co-founder of the boutique CRO, Estimeds. We uncover the shortcomings of the conventional three-plus-three design and explain how the Bayesian Optimal Interval (BOIN) design gives us more flexibility and better insights. Teppo shares practical tips on dose optimization and highlights the critical role statisticians play in shaping smarter, evidence-based decisions for phase two trials. If you want to learn how we can balance safety, efficacy, and practical challenges in oncology studies, this episode is for you!

Data drives MedTech growth, from the leanest startup to the world's most valuable pharmaceutical company. In Episode #36 of the MedTech Speed to Data Podcast, Key Tech's Andy Rogers discusses data-driven trends in medical technology with Anand Subramony, Eli Lilly's Vice President of Drug Delivery, Device, Connected Solutions & Innovation.Need to know·       Quarter-century perspective — After getting his PhD in chemistry and materials science from Purdue University, Subramony spent the next twenty-five years developing novel medical technologies for firms like Johnson & Johnson, Novartis, and AstraZeneca.·       Cutting-edge combination product development — Now at Eli Lilly, Subramony's team is responsible for combination product development, from early development through commercial development, for new delivery dosage forms.The nitty-grittySubramony drew upon his career-spanning perspective to discuss significant data-driven trends that impact the entire industry, not just Eli Lilly.One topic he raised in his conversation with Andy was using data to monitor disease state progression. Already an important element of fields like neurology and oncology, extensive data collection will become essential to a wider range of treatments. For many conditions, Subramony explains, disease state is a binary evaluation.“You can really understand disease state progression using digital biomarkers and collecting data throughout [the treatment],” Subramony said. “I think these are areas where there is a lot of potential.”Another data-driven trend Subramony discusses is the adoption of direct delivery therapies. When treating tumors and other conditions, off-target toxicity can cause unfortunate side effects. Genetic medicines, such as mRNA therapies, can target the cell surface, protect the cargo, and prevent endosomal escape.“It's going to disrupt the way we look at drug delivery from macroscopic pen auto-injector deliveries to microscopic, targeted deliveries where you need to take the therapeutic moiety into the site of action,” Subramony said.Data that made the difference:This episode's wide-ranging conversation covered many additional topics of interest to the MedTech community, including:GLP-1 treatments are “really transformative” for individual patients who can afford them. However, bringing costs down will depend on data demonstrating how lower obesity and healthier lifestyles reduce the overall burden on the healthcare system.For sensors and connected devices to go beyond “bells and whistles,” the industry must drive value from how we use that data. Relating compliance to efficacy, for example, makes moving patients from less effective to more effective therapies easier and faster.Continuous monitoring can improve healthcare outcomes but requires new data management practices to govern how much data is collected, who is collecting and viewing the data, and what are the privacy rules protecting patients. 

Could Plasmalogens Be the Key to Anti-Aging Science? In this episode of the Longevity podcast, I am welcoming  back Dr. Goodenow to discuss the incredible progress and updates in his pioneering work on plasmalogens. We explore the importance of plasmalogens in neurological development and their role in treating conditions like ALS, autism, and MS.  Plasmalogens are essential lipids found in the brain, heart, lungs, and human breast milk, crucial for early brain development and preventing neurodegenerative diseases like ALS, MS, and autism and we discuss the mechanics behind aging and diseases, stressing the importance of mitochondrial function, membrane structure, and the body's ability to repair itself.    BIO: Dr. Dayan Goodenowe is a pioneering researcher and biochemist with a profound impact on neurological and age-related diseases.  Known for his work with plasmalogens, Dr. Goodenowe has devoted over three decades to studying these critical molecules and their role in human health. His research has significantly advanced the understanding and treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, ALS, and autism, as well as conditions like COVID-19 and inflammatory disorders.   To Purchase Plasmologens use this link https://prodrome.com/?ref=NAT25 or head over to Prodrome.com and use code NAT25 to save 25% off your purchase!   Thank you to our sponsors for making this episode possible: NEUROHACKER:  Visit qualialife.com/nathalie and use code NATHALIE VITALI SKIN CARE/RESTORACELL: Visit vitaliskincare.com/discount/Nathalie20 and use code Nathalie20 to save on your order.   LVLVUP: Use code NAT15 to save 10% off at lvluphealth.com/                            Find more from DR DAYAN GOODENOWE: Website: drgoodenowe.com Instagram: @drdayangoodenowe and @prodromesciences   Find more from Nathalie: YouTube: https://www.youtube.com/channel/UCmholC48MqRC50UffIZOMOQ  Join Nat's Membership Community: https://www.natniddam.com/bsp-community  Sign up for Nats Newsletter: https://landing.mailerlite.com/webforms/landing/i7d5m0  Instagram: https://www.instagram.com/nathalieniddam/  Website: www.NatNiddam.com    Facebook Group: https://www.facebook.com/groups/biohackingsuperhumanperformance    What We Discuss: 01:22 The Importance of Plasmalogens 01:39 Our Advanced Infrastructure and Research 04:46 The Role of Plasmalogens in Early Development 06:28 Understanding Brain Development and Longevity 09:05 Restoring Health and Functionality 15:52 Parkinson's and Neurological Health 33:51 The Power of Plasmalogens in Neurogenesis 36:54 Understanding Plasmalogen Precursors 37:49 Historical Context and Importance of Plasmalogens 38:52 Challenges and Innovations in Plasmalogen Delivery 40:26 Impact of Plasmalogens on Inflammatory Diseases 41:53 Plasmalogens and Major Organ Functions 42:26 Plasmalogens in Cardiac Health and ALS 44:35 Mechanisms of ALS and Plasmalogen Therapy 50:37 Restoring Neuromuscular Function 58:02 Community Health Initiatives and Research   Key Takeaways: Plasmalogens are integral in early childhood brain development and maintaining the functionality of crucial organs like the heart and lungs. Plasmalogen deficiencies are linked to various severe health conditions, including neurodegenerative diseases. Adequate mitochondrial function is critical for mitigating the effects of chronic diseases, including autism and multiple sclerosis. Key nutrients include B vitamins, CoQ10, and carnitine.  

For more information, go to theconferenceforum.org 

DOI: 10.13056/acamh.13575 In this In Conversation podcast, Professor Sam Wass is joined by Dr. Celia Smith to discuss the science-facing findings of their JCPP Annual Research Review “‘There, the dance is – at the still point of the turning world' – dynamic systems perspectives on coregulation and dysregulation during early development” and the implications of their findings for practitioners. Learning Objectives 1. Brief overview of the methods used to study early child-caregiver interactions. 2. How new measurement techniques is driving new theory. 3. An overview of the clinical interactions currently available focused on child-caregiver interaction in the 0-3 age range. 4. Insight into six key areas relating to different processes of coregulation and dysregulation in the parent-infant pair. 5. What the reviews find in terms of cultural bias, especially as ideas around caregiver and infant interactions are often based around wester ideals, and how this can be addressed.

“What a lot of people don't quite understand about plant-based meat is that you have to understand the industry that you are replacing.” —Christie Lagally    The plant-based meat industry is at a pivotal moment, with innovative companies harnessing the power of technology to transform the way we think about sustainable protein. By seamlessly combining cutting-edge manufacturing processes and high-quality products, these visionaries are paving the way for a future where plant-based alternatives are not just viable, but the preferred choice for consumers, institutions, and the planet. At the forefront of this revolution is Christie Lagally, the CEO and Founder of Rebellyous Foods. A mechanical engineer by trade, Lagally has leveraged her expertise to develop game-changing technology that makes plant-based meat production faster, better, and more affordable than ever before. In this episode, Justine and Christie dive into the challenges of building a business around plant-based alternatives, developing the technology and market strategy to succeed, the impact of the hype cycle, funding challenges, addressing health concerns, and more.   Meet Christie:  Christie Lagally is the CEO and Founder of Rebellyous Foods, a manufacturing technology company working to make plant-based meat available and affordable for everyone. With a background as a mechanical engineer in the aerospace industry, Lagally transitioned to founding Rebellyous in 2017 to combine her personal values and professional expertise to address the negative impacts of industrial animal agriculture.  Under her leadership, Rebellyous has developed innovative processing equipment to produce high-quality, price-competitive plant-based meat products, with a focus on serving large-scale customers like school lunch programs.  Lagally is committed to creating a sustainable path forward for the meat industry to transition to plant-based production, driving positive change for the environment, human health, and animal welfare.   Website Facebook Instagram LinkedIn Connect with NextGen Purpose: Website Facebook Instagram  LinkedIn YouTube Episode Highlights: 05:01 Rebellyous Foods: Challenges and Early Development  13:05 The Hype Cycle and Its Impact 23:55 Health Concerns and Future Plans  35:06 Collaborations, Partnerships, and Exit Strategies  40:00 Future Opportunities   

We continue last week's discussion on exploration and how one can learn how to explore late in life. Download our free online video resource ⁠⁠⁠⁠⁠"The Main Signs of Attachment Disturbance" now. In this two-part video course, you'll learn how to identify the core disturbances, and how combining meditation and attachment work can help you move beyond the challenges and live a truly meaningful life. Begin your journey today at ⁠⁠⁠https://www.mettagroup.org/start-here⁠⁠⁠!

Paul Frambot, co-founder and CEO of Morpho Labs, explains how Morpho is a decentralized and permissionless lending protocol that allows users to create customized lending and borrowing pools. Unlike traditional DeFi platforms like Aave, Morpho externalizes risk management, giving users control over their risk exposure and liquidity. Frambot shares how Morpho started as a rate-optimizing solution and evolved into Morpho Blue, a more scalable protocol with over $1 billion in deposits. He discusses the advantages of building in Europe, Morpho's vision to make financial infrastructure a public good, and how fintech partnerships could drive future DeFi adoption. We also touch on Morpho's upcoming token launch and its long-term strategy to compete with other major DeFi protocols. 0:00 - Intro to Paul Frambot 0:30 - What is Morpho and How it Differs from Competitors 2:00 - Paul's Background and Entry into DeFi 3:30 - Early Development of Morpho Optimizer 5:00 - Transition to Morpho Blue and Permissionless Lending 8:00 - Managing Risk, Liquidity, and Customization 11:00 - Real-World Assets and New Use Cases in DeFi 14:00 - Challenges and Advantages of Building in Europe 18:00 - Morpho's Long-Term Vision: Financial Infrastructure as a Public Good 23:00 - Future of DeFi: Fintech Integration and Token Launch 28:00 - Competition with Aave and Growth Strategy 33:00 - The Role of Fintech in Scaling DeFi 38:00 - Long-Term Vision for DeFi and Fintech 43:00 - Morpho's Upcoming Tokenomics and Governance 48:00 - Future Trends and Adoption in DeFi 52:00 - Closing Thoughts and Paul's Outlook on DeFi This episode was sponsored by: NEAR: https://redactedbangkok.ai/?utm_source=thedefiant&utm_medium=referral&utm_campaign=defiant&utm_content=newsletter Stellar: https://stellar.org/soroban?utm_source=defiant&utm_medium=cpc&utm_campaign=defiant_podcast ✨ Check out our new website ✨ https://thedefiant.io/

On this episode we discuss exploration and how one can learn how to explore late in life. Download our free online video resource ⁠⁠⁠⁠⁠"The Main Signs of Attachment Disturbance" now. In this two-part video course, you'll learn how to identify the core disturbances, and how combining meditation and attachment work can help you move beyond the challenges and live a truly meaningful life. Begin your journey today at ⁠⁠https://www.mettagroup.org/start-here⁠⁠!

On this week's episode of Sense, by Meg Faure, we delve into the crucial topic of early development. Meg Faure welcomes Claire Stead, an educator and founder of Oliiki, to discuss the significance of the first 1000 days of life. The episode highlights the impact of early experiences, epigenetics, and the key developmental milestones that set the stage for a child's future. The Importance of the First 1000 Days Claire Stead explains why the first 1000 days, from conception to age two, are foundational for a child's development. These early years are when the brain undergoes rapid growth, laying the groundwork for all future learning and development. Stead emphasizes that this period not only shapes cognitive and academic outcomes but also emotional, social, and physical health. The environment and experiences during these critical years can influence factors like well-being, resilience, and stress responses later in life. Epigenetic's and Generational Impact A key theme of the episode is epigenetic's. The idea that environmental factors can switch genes on or off, influencing not just the individual but future generations. Stead shares fascinating research on how experiences during pregnancy and early childhood can affect gene expression, potentially impacting not only a child's health and development but also that of their grandchildren. This underscores the importance of a nurturing and stress-free pregnancy, not just for the mother but for the baby's future generations. Key Developmental Milestones The episode explores three pivotal developmental milestones: smiling, crawling, and pointing. Smiling is crucial for emotional connection, crawling is vital for physical and cognitive development, and pointing signifies communication readiness. Faure and Stead discuss why these milestones matter and how they contribute to a child's broader developmental trajectory. Practical Parenting Tips Listeners are offered practical tips to nurture their child's development. Stead emphasizes the importance of eye contact, time spent on the floor for motor development, and limiting distractions like screens to foster engagement and connection. This episode is essential listening for any parent or caregiver who wants to give their child the best start in life. Claire Stead provides valuable insights on how simple, daily interactions can lay the foundation for lifelong success. If you want to understand how early childhood development shapes your child's future, this episode is a must-listen.

On today's Midday Report with host Terry Haines: A landslide in Kenai Fiords Park caused a 55 foot tsunami last month. Search and rescue personnel had a long holiday weekend that included three plane crashes in Alaska. And Alaska's Department of Education and Early Development released statewide assessment data on Friday that shows most students are not proficient in core subjects. Photo: agle River High School students protest Gov. Mike Dunleavy's education funding veto on Thursday, April 4, 2024. A new study shows most Alaska students are not proficient in core subjects. (James Oh / Alaska Public Media)

In this episode of The Light Inside, we delve into the intricate world of emotional triggers and self-regulation. We all experience moments when a seemingly innocuous comment or situation sends us spiraling into an emotional storm. Whether it's a partner's remark or a social media comment, our emotions can distort reality, leading to unnecessary conflict and misunderstanding. We explore the concept of the autonomic ladder, a metaphorical escalator that represents our emotional states. Our guest, John Eli Gouray, provides insights into how our autonomic nervous system, through a process called neuroception, constantly scans our environment for cues of safety and danger. This system can trigger either a calm, parasympathetic response or an aroused, sympathetic response, often without our conscious awareness. John explains the three primary states of the autonomic ladder: 1. Dorsal Vagal State: Associated with feelings of shutdown, immobilization, and despair.2. Sympathetic State: Characterized by activation, anxiety, and a desire for movement or conflict.3. Ventral Vagal State: The state of safety, social connection, and calm. Exploring the concept of emotional triggers, this episode delves into how seemingly harmless interactions can escalate into overwhelming emotional storms. From conversations with partners to comments on social media, our reactions can be driven by our emotions, altering our perceptions and leading to unnecessary conflict. The episode questions why it's challenging to control these reactions and sheds light on the autonomic ladder, illustrating how we can quickly spiral into misunderstandings when triggered emotionally. 00:00:00 - Introduction to Emotional Triggers00:00:10 - Real-Life Examples of Emotional Triggers00:01:03 - Impact of Emotional Reactions00:01:24 - The Autonomic Ladder Explained00:02:06 - Sponsor Message: Mint Mobile00:03:42 - Understanding Nervous System Responses00:05:09 - The Role of Neuroception00:07:11 - Early Development of Emotional Patterns00:08:48 - Emotions vs. Feelings00:10:00 - Story Follows State00:11:32 - Inference and Transference in Emotional Responses00:14:10 - Autonomic Nervous System and Childhood Experiences00:17:17 - The Autonomic Ladder: Detailed Breakdown00:20:00 - Dorsal Vagal Response00:23:21 - Sympathetic State and Overachieving00:27:13 - Personal Story: Work and Self-Worth00:30:16 - Sympathetic Phase of Response00:33:31 - Motivations Behind Emotional Responses00:34:35 - Identifying Emotional States00:38:08 - Hypervigilance and Emotional Reactivity00:40:35 - Example: Walking Through a Dark Pathway00:41:13 - Ventral Vagal Response00:43:03 - Pets and Emotional Regulation00:44:31 - Intuitive Awareness of Emotional Triggers00:45:52 - Identifying Triggers and Glimmers00:48:04 - Physical Movement and Emotional Relief00:49:07 - Emotional Cleaning as an Outlet00:50:19 - Labeling and Stigmatizing Behaviors00:52:44 - Personal Experiences with Sun Exposure00:53:38 - Assumptions and Projections in Interactions00:54:33 - The Practice of Asking and Clarifying JOIN US ON INSTAGRAM: @thelightinsidepodcast SUBSCRIBE: pod.link/thelightinside https:www.thelightinside.site Credits: Featured Guest: John Eli Guray Music Score: Epidemic Sound Executive Producer: Jeffrey Besecker Mixing, Engineering, Production and Mastering: Aloft Media Executive Program Director: Anna Getz

Peter Burke, Minister for Enterprise, Trade and Employment, on a record 250 million euro allocation to an Enterprise Ireland scheme to provide funding for Irish companies in their early stages of development.

“An Appointment with Yourself” is the second class in a five part series on the Breath hosted by Pernilla Burke and Abdi Assadi. In this class we discuss  the importance of proper breathing techniques for mindfulness and emotional regulation.  We provide practical tools to increase awareness and create moments of pause in daily life. The class emphasizes that many people breathe shallowly from the upper lungs due to chronic anxiety. Abdi explains that shallow thoracic breathing suppresses emotions and disconnects us from our bodies. They advocate for "belly breathing," where the lower lobes of the lungs are filled, increasing oxygen intake and helping release repressed emotions. The class aims to help listeners re-train their breathing patterns, highlighting the physiological and emotional benefits of mindful breathing. Pernilla and Abdi's insights encourage incorporating these techniques into daily routines for improved well-being and conscious living. (00:00) Introduction: Introduction by Pernilla Burke and Abdi Assadi. Overview of the purpose of the Awakening 101 classes. (01:01) Importance of Breath: Discussion on the significance of breath for mindfulness. Brief mention of the personal journey with breathwork. (03:01) Shallow Breathing and Anxiety: Explanation of shallow thoracic breathing. Connection between anxiety and shallow breathing. (05:31) Belly Breathing Technique: Introduction to belly breathing. Explanation of how it fills the lower lungs. (07:31) Emotional and Physical Benefits: Benefits of proper breathwork on emotional regulation. Discussion on how breathing can help release repressed emotions. (10:01) Early Development of Breathing Patterns. How shallow breathing patterns develop from a young age. Impact of trauma on breathing. (12:01) Practical Tips for Daily Life: Practical tips for incorporating proper breathing into daily routines. Encouragement to practice mindful breathing for improved well-being. (14:01) Personal Experiences and Conclusion. Abdi and Pernilla share personal experiences with breathwork. Final thoughts and encouragement to viewers.

This week, I welcome Brent Leuthold back to the show to review Twisters in both a non-spoiler and spoiler feature review. Then, in this week's secondary review, we share our thoughts on Fly Me to the Moon. We also talk about recent news regarding Severance season 2, Bob Newhart's passing, a possible 24 movie, Noah Hawley's Alien: Earth, and more.   Timestamps   Show Start - 00:28 News - 05:43 Thoughts on Twister (1996) - 36:57   Feature Review   Twisters (2024) - 43:49 Spoiler - 1:15:29   Secondary Review   Fly Me to the Moon (2024) - 1:45:07   Closing the Ep - 2:03:38 Patreon Clip - 2:06:33   Related Links   Start Your Podcast with Libsyn Using Promo Code OBSESS '24' Film in Early Development at 20th Century, Produced By Brian Grazer Bob Newhart, Comedy Icon, Dies at 94 Russo Brothers Make Big Return To Marvel As They Eye Upcoming ‘Avengers' Sequels FX's ‘Alien' Series Wraps Filming, Showrunner Noah Hawley Promises “Something Special” ‘Severance' Season 2 Teaser Unveils 2025 Release Date and Gwendoline Christie's Mysterious New Character   Brent's Letterboxd Awake in the Dark Brent's Review of Twisters Brent's Review of Longlegs Brent's Review of Fly Me to the Moon   My 2024 Podcast and Writing Archive One Year of Criterion Channel - Dec 24, 2023 - Dec 23, 2024 Movies I Own But Haven't Watched/Rated Yet   Follow Us on Social Media My Letterboxd | YouTube | Facebook | Twitter/X Instagram | Threads | Bluesky | TikTok | Tiny's Letterboxd   Subscribe to the Podcast Apple Podcasts | Spotify | Audible   Support Us on Patreon for Exclusive Content Official OV Merch  Obsessive Viewer Obsessive Viewer Presents: Anthology Obsessive Viewer Presents: Tower Junkies As Good As It Gets - Linktree   Mic Info Matt: ElectroVoice RE20 into RØDEcaster Pro II (Firmware: 1.3.4) Brent: Earthworks ICON Pro in Google Meet   Episode Homepage: ObsessiveViewer.com/OV435   Next Week on the Podcast OV436 - Deadpool & Wolverine (2024) & TBD

In Season 2 Episode 33 of our Montessori Babies Podcast, I had the pleasure of chatting with Dr. Liraz all about boosting brain development in the early years! She is a neuroscientist and Mama who has a love for all things Montessori.This week we discussed:brain boosting from birth - 6 yearsbrain development beyond childhoodtangible tools to boost brain development everydayhow to support your own brain as a new MamaAnd more!Dr. Liraz's website: https://littleneurons.com2nd Live International Montessori SeminarSeptember 7, 2024 - 9:00 AM - Noon CDT - Live on ZoomDon't miss this upcoming high quality, hands-on International Montessori seminar! The amazing panel of speakers are ready to help you and your child take Montessori education to the next level. Come learn from the experts, win FREE Montessori prizes, and make new friends! Learn and earn $1000 worth of prizes in our raffle, including personalized coaching, educational books, innovative toys, and so much more!Connect with like-minded educators and parents passionate about Montessori education during our breakout sessions. **EARLY BIRD SPECIAL: **Enter LVLUP20 for a 20% discount at checkout.*SPACES ARE LIMITED!! *REGISTER NOW and receive a FREE GIFT here:

Send us a Text Message.Effect of Low-Dose Iron Supplementation on Early Development in Breastfed Infants: A Randomized Clinical Trial.Svensson L, Chmielewski G, Czyzewska E, Domellöf M, Konarska Z, Piescik-Lech M, Späth C, Szajewska H, Chmielewska A.JAMA Pediatr. 2024 Jul 1;178(7):649-656. doi: 10.1001/jamapediatrics.2024.1095.PMID: 38739382 Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

On this week's episode of Sense, by Meg Faure, we dive into the incredible journey of early brain development. Our guest host, Tove Gant, joins us to explore how sensory stimulation shapes the human brain in the first thousand days. This episode is essential for parents keen on optimising their child's cognitive, emotional, and social skills. The Importance of Early Brain Development We discuss why the first thousand days of a child's life are crucial. Meg explains how sensory experiences significantly influence brain development during this period. Listeners will learn about the concept of neuroplasticity and how the brain remains moldable throughout life. Sensory Stimulation and Neuroplasticity Meg elaborates on how sensory inputs create connections between brain cells. She explains how sensory stimulation impacts the brain's development and the concept of "use it or lose it." Parents will understand the importance of providing varied sensory experiences to their children. Environmental Influence The conversation highlights the role of the environment in shaping the brain. Meg shares a compelling story about a child from Hong Kong who faced developmental delays due to limited environmental exposure. This example underscores the significance of varied and rich sensory environments. Emotional Engagement and Learning Meg and Tove discuss the impact of emotional engagement on sensory stimulation. Fun and happiness are crucial for effective learning. They explain how positive emotional interactions can foster better brain development and social skills. Balancing Stimulation and Overstimulation One of the key discussions is finding the right balance between stimulation and overstimulation. Meg emphasizes the importance of reading a baby's signals to avoid overstimulation. Parents learn how to provide appropriate sensory experiences without overwhelming their children. The TEAT Framework Meg introduces the TEAT framework (Timing, Environment, Activity, and Toys) from her Baby Sense book. This framework helps parents integrate sensory stimulation into daily routines effectively. The TEAT framework ensures that activities are appropriately timed and varied throughout the day. Practical Tips for Parents Throughout the episode, Meg offers practical tips for parents to enhance sensory stimulation. She emphasizes the importance of floor time, tummy time, and using natural environments for sensory experiences. Listeners should tune in to this episode to gain valuable insights into early brain development. Meg Faure provides actionable advice and scientific explanations, making this podcast a must-listen for new parents. By understanding and applying these principles, parents can significantly impact their child's future cognitive, emotional, and social success. This episode offers a comprehensive guide to fostering optimal brain development through sensory stimulation.

New research finds that iron supplementation for low-risk breastfed infants born at term does not improve psychomotor development. JAMA Pediatrics Editor in Chief Dimitri Christakis, MD, MPH, and JAMA Pediatrics Associate Editor Alison Galbraith, MD, MPH, discuss infant iron supplementation with Martha Sola-Visner, MD, associate professor at Boston Children's Hospital and Harvard Medical School. Related Content: Effect of Low-Dose Iron Supplementation on Early Development in Breastfed Infants

On today's Midday Report with host Terry Haines: The Coast Guard's plan to build three heavy icebreakers is years behind schedule and the price has ballooned. The Alaska Legislature shot down one of Gov. Mike Dunleavy's nominees to the state Board of Education and Early Development on Tuesday. And Kinross's partner in the Manh Choh Mine has agreements to acquire some new Alaska gold prospects.

Welcome to a new episode of The Founder Podcast. In this episode, we explore Alex Neist's journey from the depths of personal and professional despair to the heights of entrepreneurial success with Hostage Tape. Discover how a simple change in his sleep habits led to a profound transformation in his life and sparked the creation of a brand that's much more than just a product—it's a movement. Alex shares the incredible story behind Hostage Tape, revealing how it not only improved his own life but also promises to revolutionize sleep for millions. Highlights: "I'm building a billion dollar brand. It is—I know it is. I can see where it's going to be. And I know what the TAM is, I know what the opportunity is." "This isn't just tape. It's a movement." "I need something that I'm I love doing and I love building. I love building these companies." Timestamps: 00:00 - Introduction to Hostage Tape 02:08 - Origin Story of Hostage Tape 05:08 - Early Development of Hostage Tape 10:48 - Naming the 'Hostage' Brand 16:41 - Marketing and Brand Evolution 22:40 - Protecting Product Innovations 30:09 - Building a Brand Community 34:50 - Team Culture and Philosophy 42:17 - Future Vision and Strategy 45:15 - Influential Books and Resources Looking to scale your business? Want to learn directly from the same team that helped me sell my last business for 9 figures? Click this link below to check out how you can work with us. https://nextlevelhomepros.com/grow-home-service-vsl Join my community - Founder Acceleration ⁠https://www.founderacceleration.com ⁠Apply for our next Mastermind: h⁠ttps://www.thefoundermastermind.com⁠Golf with Chris h⁠ttps://www.golfwithchris.com⁠Watch my latest PodcastApple- ⁠https://podcasts.apple.com/us/podcast/the-founder-podcast/id1687030281S⁠Spotify- ⁠https://open.spotify.com/show/1e0cL2vI1JAtQrojSOA7D2⁠YouTube - @thefounderspodcast

“Where do I think the next amazing revolution is going to come? … There's no question that digital biology is going to be it. For the very first time in our history, in human history, biology has the opportunity to be engineering, not science.” —Jensen Huang, NVIDIA CEOAviv Regev is one of the leading life scientists of our time. In this conversation, we cover the ongoing revolution in digital biology that has been enabled by new deep knowledge on cells, proteins and genes, and the use of generative A.I .Transcript with audio and external linksEric Topol (00:05):Hello, it's Eric Topol with Ground Truths and with me today I've really got the pleasure of welcoming Aviv Regev, who is the Executive Vice President of Research and Early Development at Genentech, having been 14 years a leader at the Broad Institute and who I view as one of the leading life scientists in the world. So Aviv, thanks so much for joining.Aviv Regev (00:33):Thank you for having me and for the very kind introduction.The Human Cell AtlasEric Topol (00:36):Well, it is no question in my view that is the truth and I wanted to have a chance to visit a few of the principal areas that you have been nurturing over many years. First of all, the Human Cell Atlas (HCA), the 37 trillion cells in our body approximately a little affected by size and gender and whatnot, but you founded the human cell atlas and maybe you can give us a little background on what you were thinking forward thinking of course when you and your colleagues initiated that big, big project.Aviv Regev (01:18):Thanks. Co-founded together with my very good friend and colleague, Sarah Teichmann, who was at the Sanger and just moved to Cambridge. I think our community at the time, which was still small at the time, really had the vision that has been playing out in the last several years, which is a huge gratification that if we had a systematic map of the cells of the body, we would be able both to understand biology better as well as to provide insight that would be meaningful in trying to diagnose and to treat disease. The basic idea behind that was that cells are the basic unit of life. They're often the first level at which you understand disease as well as in which you understand health and that in the human body, given the very large number of individual cells, 37.2 trillion give or take, and there are many different characteristics.(02:16):Even though biologists have been spending decades and centuries trying to characterize cells, they still had a haphazard view of them and that the advancing technology at the time – it was mostly single cell genomics, it was the beginnings also of spatial genomics – suggested that now there would be a systematic way, like a shared way of doing it across all cells in the human body rather than in ways that were niche and bespoke and as a result didn't unify together. I will also say, and if you go back to our old white paper, you will see some of it that we had this feeling because many of us were computational scientists by training, including both myself and Sarah Teichmann, that having a map like this, an atlas as we call it, a data set of this magnitude and scale, would really allow us to build a model to understand cells. Today, we call them foundational models or foundation models. We knew that machine learning is hungry for these kinds of data and that once you give it to machine learning, you get amazing things in return. We didn't know exactly what those things would be, and that has been playing out in front of our eyes as well in the last couple of years.Spatial OmicsEric Topol (03:30):Well, that gets us to the topic you touched on the second area I wanted to get into, which is extraordinary, which is the spatial omics, which is related to the ability to the single cell sequencing of cells and nuclei and not just RNA and DNA and methylation and chromatin. I mean, this is incredible that you can track the evolution of cancer, that the old word that we would say is a tumor is heterogeneous, is obsolete because you can map every cell. I mean, this is just changing insights about so much of disease health mechanisms, so this is one of the hottest areas of all of life science. It's an outgrowth of knowing about cells. How do you summarize this whole era of spatial omics?Aviv Regev (04:26):Yeah, so there's a beautiful sentence in the search for lost time from Marcel Proust that I'm going to mess up in paraphrasing, but it is roughly that going on new journeys is not about actually going somewhere physically but looking with new eyes and I butchered the quote completely.[See below for actual quote.] I think that is actually what single cells and then spatial genomics or spatial omics more broadly has given us. It's the ability to look at the same phenomenon that we looked at all along, be it cancer or animal development or homeostasis in the lung or the way our brain works, but having new eyes in looking and because these new eyes are not just seeing more of something we've seen before, but actually seeing things that we couldn't realize were there before. It starts with finding cells we didn't know existed, but it's also the processes that these cells undergo, the mechanisms that actually control that, the causal mechanisms that control that, and especially in the case of spatial genomics, the ways in which cells come together.(05:43):And so we often like to think about the cell because it's the unit of life, but in a multicellular organism we just as much have to think about tissues and after that organs and systems and so on. In a tissue, you have this amazing orchestration of the interactions between different kinds of cells, and this happens in space and in time and as we're able to look at this in biology often structure is tightly associated to function. So the structure of the protein to the function of the protein in the same way, the way in which things are structured in tissue, which cells are next to each other, what molecules are they expressing, how are they physically interacting, really tells us how they conduct the business of the tissue. When the tissue functions well, it is this multicellular circuit that performs this amazing thing known as homeostasis.(06:36):Everything changes and yet the tissue stays the same and functions, and in disease, of course, when these connections break, they're not done in the right way you end up with pathology, which is of course something that even historically we have always looked at in the level of the tissue. So now we can see it in a much better way, and as we see it in a better way, we resolve better things. Yes, we can understand better the mechanisms that underlie the resistance to therapeutics. We can follow a temporal process like cancer as it unfortunately evolves. We can understand how autoimmune disease plays out with many cells that are actually bent out of shape in their interactions. We can also follow magnificent things like how we start from a single cell, the fertilized egg, and we become 37.2 trillion cell marvel. These are all things that this ability to look in a different way allows us to do.Eric Topol (07:34):It's just extraordinary. I wrote at Ground Truths about this. I gave all the examples at that time, and now there's about 50 more in the cardiovascular arena, knowing with single cell of the pineal gland that the explanation of why people with heart failure have sleep disturbances. I mean that's just one of the things of so many now these new insights it's really just so remarkable. Now we get to the current revolution, and I wanted to read to you a quote that I have.Digital BiologyAviv Regev (08:16):I should have prepared mine. I did it off the top of my head.Eric Topol (08:20):It's actually from Jensen Huang at NVIDIA about the digital biology [at top of the transcript] and how it changes the world and how you're changing the world with AI and lab in the loop and all these things going on in three years that you've been at Genentech. So maybe you can tell us about this revolution of AI and how you're embracing it to have AI get into positive feedbacks as to what experiment to do next from all the data that is generated.Aviv Regev (08:55):Yeah, so Jensen and NVIDIA are actually great partners for us in Genentech, so it's fun to contemplate any quote that comes from there. I'll actually say this has been in the making since the early 2010s. 2012 I like to reflect on because I think it was a remarkable year for what we're seeing right now in biology, specifically in biology and medicine. In 2012, we had the beginnings of really robust protocols for single cell genomics, the first generation of those, we had CRISPR happen as a method to actually edit cells, so we had the ability to manipulate systems at a much better way than we had before, and deep learning happened in the same year as well. Wasn't that a nice year? But sometimes people only realize the magnitude of the year that happened years later. I think the deep learning impact people realized  first, then the single cells, and then the CRISPR, then the single cells.(09:49):So in order maybe a little bit, but now we're really living through what that promise can deliver for us. It's still the early days of that, of the delivery, but we are really seeing it. The thing to realize there is that for many, many of the problems that we try to solve in biomedicine, the problem is bigger than we would ever be able to perform experiments or collect data. Even if we had the genomes of all the people in the world, all billions and billions of them, that's just a smidge compared to all of the ways in which their common variants could combine in the next person. Even if we can perturb and perturb and perturb, we cannot do all of the combinations of perturbations even in one cell type, let alone the many different cell types that are out there. So even if we searched for all the small molecules that are out there, there are 10 to the 60 that have drug-like properties, we can't assess all of them, even computationally, we can't assess numbers like that.(10:52):And so we have to somehow find a way around problems that are as big as that and this is where the lab in the loop idea comes in and why AI is so material. AI is great, taking worlds, universes like that, that appear extremely big, nominally, like in basic numbers, but in fact have a lot of structure and constraint in them so you can reduce them and in this reduced latent space, they actually become doable. You can search them, you can compute on them, you can do all sorts of things on them, and you can predict things that you wouldn't actually do in the real world. Biology is exceptionally good, exceptionally good at lab sciences, where you actually have the ability to manipulate, and in biology in particular, you can manipulate at the causes because you have genetics. So when you put these two worlds together, you can actually go after these problems that appear too big that are so important to understanding the causes of disease or devising the next drug.(11:51):You can iterate. So you start, say, with an experimental system or with all the data that you have already, I don't know from an initiative like the human cell atlas, and from this you generate your original model of how you think the world works. This you do with machine learning applied to previous data. Based on this model, you can make predictions, those predictions suggest the next set of experiments and you can ask the model to make the most optimized set of predictions for what you're trying to learn. Instead of just stopping there, that's a critical point. You go back and you actually do an experiment and you set up your experiments to be scaled like that to be big rather than small. Sometimes it means you actually have to compromise on the quality of any individual part of the experiment, but you more than make up for that with quantity.The A.I. Lab-in-the-Loop(12:38):So now you generate the next data from which you can tell both how well did your algorithm actually predict? Maybe the model didn't predict so well, but you know that because you have lab results and you have more data in order to repeat the loop, train the model again, fit it again, make the new next set of predictions and iterate like this until you're satisfied. Not that you've tried all options, because that's not achievable, but that you can predict all the interesting options. That is really the basis of the idea and it applies whether you're solving a general basic question in biology or you're interested in understanding the mechanism of the disease or you're trying to develop a therapeutic like a small molecule or a large molecule or a cell therapy. In all of these contexts, you can apply this virtual loop, but to apply it, you have to change how you do things. You need algorithms that solve problems that are a little different than the ones they solved before and you need lab experiments that are conducted differently than they were conducted before and that's actually what we're trying to do.Eric Topol (13:39):Now I did find the quote, I just want to read it so we have it, “biology has the opportunity to be engineering, not science. When something becomes engineering, not science, it becomes exponentially improving. It can compound on the benefits of previous years.” Which is kind of a nice summary of what you just described. Now as we go forward, you mentioned the deep learning origin back at the same time of CRISPR and so many things happening and this convergence continues transformer models obviously one that's very well known, AlphaFold, AlphaFold2, but you work especially in antibodies and if I remember correctly from one of your presentations, there's 20 to the 32nd power of antibody sequences, something like that, so it's right up there with the 10 to the 60th number of small molecules. How do transformer models enhance your work, your discovery efforts?Aviv Regev (14:46):And not just in antibodies, I'll give you three brief examples. So absolutely in antibodies it's an example where you have a very large space and you can treat it as a language and transformers are one component of it. There's other related and unrelated models that you would use. For example, diffusion based models are very useful. They're the kind that people are used to when you do things, you use DALL-E or Midjourney and so on makes these weird pictures, think about that picture and not as a picture and now you're thinking about a three-dimensional object which is actually an antibody, a molecule. You also mentioned AlphaFold and AlphaFold 2, which are great advances with some components related to transformers and some otherwise, but those were done as general purpose machines for proteins and antibodies are actually not general purpose proteins. They're antibodies and therapeutic antibodies are even further constrained.(15:37):Antibodies also really thrive, especially for therapeutics and also in our body, they need diversity and many of these first models that were done for protein structure really focused on using conservation as an evolutionary signal comparison across species in order to learn the model that predicts the structure, but with antibodies you have these regions of course that don't repeat ever. They're special, they're diverse, and so you need to do a lot of things in the process in order to make the model fit in the best possible way. And then again, this loop really comes in. You have data from many, many historical antibodies. You use that to train the model. You use that model in order to make particular predictions for antibodies that you either want to generate de novo or that you want to optimize for particular properties. You make those actually in the lab and in this way gradually your models become better and better at this task with antibodies.(16:36):I do want to say this is not just about antibodies. So for example, we develop cancer vaccines. These are personalized vaccines and there is a component in making a personalized cancer vaccine, which is choosing which antigens you would actually encode into the vaccine and transformers play a crucial role in actually making this prediction today of what are good neoantigens that will get presented to the immune system. You sometimes want to generate a regulatory sequence because you want to generate a better AAV-like molecule or to engineer something in a cell therapy, so you want to put a cis-regulatory sequence that controls gene expression. Actually personally for me, this was the first project where I used a transformer, which we started years ago. It was published a couple of years ago where we learned a general model that can predict in a particular system. Literally you throw a sequence at that model now and it will predict how much expression it would drive. So these models are very powerful. They are not the be all and end all of all problems that we have, but they are fantastically useful, especially for molecular therapeutics.Good Trouble: HallucinationsEric Topol (17:48):Well, one of the that has been an outgrowth of this is to actually take advantage of the hallucinations or confabulation of molecules. For example, the work of David Baker, who I'm sure you know well at University of Washington, the protein design institute. We are seeing now molecules, antibodies, proteins that don't exist in nature from actually, and all the things that are dubbed bad in GPT-4 and ChatGPT may actually help in the discovery in life science and biomedicine. Can you comment about that?Aviv Regev (18:29):Yeah, I think much more broadly about hallucinations and what you want to think about is something that's like constrained hallucination is how we're creative, right? Often people talk about hallucinations and they shudder at it. It sounds to them insane because if you think about your, say a large language model as a search tool and it starts inventing papers that don't exist. You might be like, I don't like that, but in reality, if it invents something meaningful that doesn't exist, I love that. So that constrained hallucination, I'm just using that colloquially, is a great property if it's constrained and harnessed in the right way. That's creativity, and creativity is very material for what we do. So yes, absolutely in what we call the de novo domain making new things that don't exist. This generative process is the heart of drug discovery. We make molecules that didn't exist before.(19:22):They have to be imagined out of something. They can't just be a thing that was there already and that's true for many different kinds of therapeutic molecules and for other purposes as well, but of course they still have to function in an effective way in the real world. So that's where you want them to be constrained in some way and that's what you want out of the model. I also want to say one of the areas that personally, and I think for the field as a whole, I find the most exciting and still underused is the capacity of these models to hallucinate for us or help us with the creative endeavors of identifying the causes of processes, which is very different than the generative process of making molecules. Thinking about the web of interactions that exist inside a cell and between cells that drives disease processes that is very hard for us to reason through and to collect all the bits of information and to fill in blanks, those fillings of the blanks, that's our creativity, that's what generates the next hypothesis for us. I'm very excited about that process and about that prospect, and I think that's where the hallucination of models might end up proving to be particularly impressive.A.I. Accelerated Drug DiscoveryEric Topol (20:35):Yeah. Now obviously the field of using AI to accelerate drug discovery is extremely hot, just as we were talking about with spatial omics. Do you think that is warranted? I mean you've made a big bet on that you and your folks there at Genentech of course, and so many others, and it's a very crowded space with so many big pharma partnering with AI. What do you see about this acceleration? Is it really going to reap? Is it going to bear fruit? Are we going to see, we've already seen some drugs of course, that are outgrowths, like Baricitinib in the pandemic and others, but what are your expectations? I know you're not one to get into any hyperbole, so I'm really curious as to what you think is the future path.Aviv Regev (21:33):So definitely my hypothesis is that this will be highly, highly impactful. I think it has the potential to be as impactful as molecular biology has been for drug discovery in the 1970s and 1980s. We still live that impact. We now take it for granted. But, of course that's a hypothesis. I also believe that this is a long game and it's a deep investment, meaning decorating what you currently do with some additions from right and left is not going to be enough. This lab in the loop requires deep work working at the heart of how you do science, not as an add-on or in addition to or yet another variant on what has become a pretty established approach to how things are done. That is where I think the main distinction would be and that requires both the length of the investment, the effort to invest in, and also the willingness to really go all out, all in and all out.(22:36):And that takes time. The real risk is the hype. It's actually the enthusiasm now compared to say 2020 is risky for us because people get very enthusiastic and then it doesn't pay off immediately. No, these iterations of a lab in the loop, they take time and they take effort and they take a lot of changes and at first, algorithms often fail before they succeed. You have to iterate them and so that is actually one of the biggest risks that people would be like, but I tried it. It didn't work. This was just some over-hyped thing. I'm walking away and doing it the old way. So that's where we actually have to keep at it, but also keep our expectations not low in magnitude. I think that it would actually deliver, but understanding that it's actually a long investment and that unless you do it deeply, it's not going to deliver the goods.Eric Topol (23:32):I think this point warrants emphasis because the success already we've seen has not been in necessarily discovery and in preliminary validation of new molecules, but rather data mining repurposing, which is a much easier route to go quicker, but also there's so many nodes on past whereby AI can make a difference even in clinical trials, in synthetic efforts to project how a clinical trial will turn out and being able to do toxic screens without preclinical animal work. There's just so many aspects of this that are AI suited to rev it up, but the one that you're working on, of course is the kind of main agenda and I think you framed it so carefully that we have to be patient here, that it has a chance to be so transformative. Now, you touched on the parallels to things like DALL-E and Midjourney and large language models. A lot of our listeners will be thinking only of ChatGPT or GPT-4 or others. This is what you work on, the language of life. This is not text of having a conversation with a chatbot. Do you think that as we go forward, that we have to rename these models because they're known today as language models? Or do you think that, hey, you know what, this is another language. This is a language that life science and biomedicine works with. How do you frame it all?Large Non-Human Language ModelsAviv Regev (25:18):First of all, they absolutely can remain large language models because these are languages, and that's not even a new insight. People have treated biological sequences, for example, in the past too, using language models. The language models were just not as great as the ones that we have right now and the data that were available to train models in the past were not as amazing as what we have right now. So often these are really the shifts. We also actually should pay respect to human language. Human language encodes a tremendous amount of our current scientific knowledge and even language models of human language are tremendously important for this scientific endeavor that I've just described. On top of them come language models of non-human language such as the language of DNA or the language of protein sequences, which are also tremendously important as well as many other generative models, representation learning, and other approaches for machine learning that are material for handling the different kinds of data and questions that we have.(26:25):It is not a single thing. What large language models and especially ChatGPT, this is an enormous favor for which I am very grateful, is that I think it actually convinced people of the power. That conviction is extremely important when you're solving a difficult problem. If you feel that there's a way to get there, you're going to behave differently than if you're like, nothing will ever come out of it. When people experience ChatGPT actually in their daily lives in basic things, doing things that felt to them so human, this feeling overrides all the intellectual part of things. It's better than the thinking and then they're like, in that case, this could actually play out in my other things as well. That, I think, was actually materially important and was a substantial moment and we could really feel it. I could feel it in my interactions with people before and after how their thinking shifted. Even though we were on this journey from before.Aviv Regev (27:30):We were. It felt different.Eric Topol (27:32):Right, the awareness of hundreds of millions of people suddenly in end of November 2022 and then you were of course going to Genentech years before that, a couple few years before that, and you already knew this was on the move and you were redesigning the research at Genentech.Aviv Regev (27:55):Yes, we changed things well before, but it definitely helps in how people embrace and engage feels different because they've seen something like that demonstrated in front of them in a way that felt very personal, that wasn't about work. It's also about work, but it's about everything. That was very material actually and I am very grateful for that as well as for the tool itself and the many other things that this allows us to do but we have, as you said, we have been by then well on our way, and it was actually a fun moment for that reason as well.Eric Topol (28:32):So one of the things I'm curious about is we don't think about the humans enough, and we're talking about the models and the automation, but you have undoubtedly a large team of computer scientists and life scientists. How do you get them to interact? They're of course, in many respects, in different orbits, and the more they interact, the more synergy will come out of that. What is your recipe for fostering their crosstalk?Aviv Regev (29:09):Yeah, this is a fantastic question. I think the future is in figuring out the human question always above all and usually when I draw it, like on the slide, you can draw the loop, but we always put the people in the center of that loop. It's very material to us and I will highlight a few points. One crucial thing that we've done is that we made sure that we have enough critical mass across the board, and it played out in different ways. For example, we built a new computational organization, gRED Computational Sciences, from what was before many different parts rather than one consolidated whole. Of course within that we also built a very strong AI machine learning team, which we didn't have as much before, so some of it was new people that we didn't have before, but some of it was also putting it with its own identity.(29:56):So it is just as much, not more, but also not less just as much of a pillar, just as much of a driver as our biology is, as our chemistry and molecule making is, as our clinical work is. This equal footing is essential and extremely important. The second important point is you really have to think about how you do your project. For example, when we acquired Prescient, at the time they were three people, tiny, tiny company became our machine learning for drug discovery. It's not tiny anymore, but when we acquired them, we also invested in our antibody engineering so that we could do antibody engineering in a lab in the loop, which is not how we did it before, which meant we invested in our experiments in a different way. We built a department for cell and tissue genomics so we can conduct biology experiments also in a different way.(30:46):So we changed our experiments, not just our computation. The third point that I think is really material, I often say that when I'm getting asked, everyone should feel very comfortable talking with an accent. We don't expect our computational scientists to start behaving like they were actually biology trained in a typical way all along, or chemists trained in a typical way all along and by the same token, we don't actually expect our biologists to just embrace wholeheartedly and relinquish completely one way of thinking for another way of thinking, not at all. To the contrary, we actually think all these accents, that's a huge strength because the computer scientist thinks about biology or about chemistry or about medical work differently than a medical doctor or a chemist or a biologist would because a biologist thinks about a model differently and sometimes that is the moment of brilliance that defines the problem and the model in the most impactful way.(31:48):We want all of that and that requires both this equal footing and this willingness to think beyond your domain, not just hand over things, but actually also be there in this other area where you're not the expert but you're weird. Talking with an accent can actually be super beneficial. Plus it's a lot of fun. We're all scientists, we all love learning new things. So that's some of the features of how we try to build that world and you kind of do it in the same way. You iterate, you try it out, you see how it works, and you change things. It's not all fixed and set in stone because no one actually wrote a recipe, or at least I didn't find that cookbook yet. You kind of invent it as you go on.Eric Topol (32:28):That's terrific. Well, there's so much excitement in this convergence of life science and the digital biology we've been talking about, have I missed anything? We covered human cell atlas, the spatial omics, the lab in the loop. Is there anything that I didn't touch on that you find important?Aviv Regev (32:49):There's something we didn't mention and is the reason I come to work every day and everyone I work with here, and I actually think also the people of the human cell atlas, we didn't really talk about the patients.(33:00):There's so much, I think you and I share this perspective, there's so much trepidation around some of these new methods and we understand why and also we all saw that technology sometimes can play out in ways that are really with unintended consequences, but there's also so much hope for patients. This is what drives people to do this work every day, this really difficult work that tends not to work out much more frequently than it works out now that we're trying to move that needle in a substantial way. It's the patients, and that gives this human side to all of it. I think it's really important to remember. It also makes us very responsible. We look at things very responsibly when we do this work, but it also gives us this feeling in our hearts that is really unbeatable, that you're doing it for something good.Eric Topol (33:52):I think that emphasis couldn't be more appropriate. One of the things I think about all the time is that because we're moving into this, if you will, hyper accelerated phase of discovery over the years ahead with this just unparallel convergence of tools to work with, that somebody could be cured of a condition, somebody could have an autoimmune disease that we will be able to promote tolerogenicity and they wouldn't have the autoimmune disease and if they could just sit tight and wait a few years before this comes, as opposed to just missing out because it takes time to get this all to gel. So I'm glad you brought that up, Aviv, because I do think that's what it's all about and that's why we're cheering for your work and so many others to get it done, get across the goal line because there's these 10,000 diseases out there and there's so many unmet needs across them where we don't have treatments that are very effective or have all sorts of horrible side effects. We don't have cures, and we've got all the things now, as we've mentioned here in this conversation, whether it's genome editing and ability to process massive scale data in a way that never could be conceived some years ago. Let's hope that we help the patients, and go ahead.Aviv Regev (35:25):I found the Proust quote, if you want it recorded correctly.Eric Topol (35:29):Yeah, good.Aviv Regev (35:30):It's much longer than what I did. It says, “the only true voyage, the only bath in the Fountain of Youth would be not to visit strange lands but to possess other eyes, to see the universe through the eyes of another, of a hundred others, to see the hundred universes that each of them sees, that each of them is; and this we do, with great artists; with artists like these we do fly from star to star.”—Marcel ProustEric Topol (35:57):I love that and what a wonderful way to close our conversation today. Aviv, I look forward to more conversations with you. You are an unbelievable gem. Thanks so much for joining today.Aviv Regev (36:10):Thank you so much.*************************************Thanks for listening or reading to this Ground Truths Podcast.Please share if you found it of interestThe Ground Truths newsletters and podcasts are all free, open-access, without ads.Voluntary paid subscriptions all go to support Scripps Research. Many thanks for that—they greatly helped fund our summer internship programs for 2023 and 2024.Note: you can select preferences to receive emails about newsletters, podcasts, or all I don't want to bother you with an email for content that you're not interested in.Comments are welcome from all subscribers. Get full access to Ground Truths at erictopol.substack.com/subscribe

Kacie and Gianna are joined by mom of four with a passion for helping kids learn and grow to their fullest potential, Heather Mrak. Heather shares the importance of movement for your baby's brain development and understanding how our primitive reflexes contribute to the process of maturing the brain. She has over ten years of experience using cutting-edge brain training techniques for children and is trained in Neurodevelopmental Movement Foundations (based on Dr. Mastagova and Dr.Harold Blomerg's work), Dr. Melillo's Brain Balance techniques, and Brain Gym® 101. She helps parents learn strategies and exercises that boost their baby's brain development in order to grow the strongest foundation possible for all learning.  Topics discussed in this episode: The seven intelligences The pivotal role that tummy time and crawling play in the early development Her personal journey through homeschooling and how movement-based interventions like Brain Gym supported her son's reading and writing skills Prenatal education: where to start before giving birth Essential connections between movement, attachment, and development,  The impact of environments like playpens versus restrictive containers on infant movement The importance of play: including risky play and integrating it as part of stimulative development The significance of recognizing and nurturing children's love languages Allowing children to face struggles to build self-esteem Connect with Heather: www.instagram.com/babysbestbrain www.babysbestbrain.com www.tiktok.com/@babysbestbrain101 Connect with Kacie & Gianna: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.motheruppod.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/motheruppod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@motheruppod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ View full show notes at ⁠⁠⁠www.motheruppod.com⁠⁠⁠⁠

Summary In this conversation, Mark Burik and DJ Klasnic discuss the importance of hard work and early development in beach volleyball. They talk about the challenges of not having access to qualified coaches and the need for personal coaching and self-improvement. They also discuss the benefits of having a great start and the difficulty of finding coaching. DJ shares the elements he is adding to his game, such as improving his defense and optioning skills. They also discuss the Brazilian style of coaching and the importance of observing and analyzing players before making changes. They end the conversation by discussing drills for improving defense and working on reading and positioning. In this conversation, DJ Klasnic and Mark Burik discuss various aspects of beach volleyball, including defensive techniques, the complexity of defense, the importance of technique, the value of fans and competing internationally, the beach volleyball culture in the US, favorite US partners, and the importance of energy in partnerships. DJ Klasnic also shares his thoughts on moving to Florida or California and provides information on how to find him on social media. Takeaways There are different defensive techniques in beach volleyball, and players should experiment to find what works best for them. Defense in beach volleyball is complex, and players need to constantly work on improving their technique and positioning. The US beach volleyball culture offers more opportunities and support for players compared to other countries. Players in the US should take advantage of the resources available to them and pursue international competition. Having a backup plan is important in beach volleyball, as it may not provide a sustainable income in the long term. Energy and chemistry between partners are crucial for success in beach volleyball. Chapters 00:00 Introduction 01:23 The Importance of Hard Work and Early Development 05:58 The Need for Personal Coaching and Self-Improvement 08:19 The Minimum Requirement for Improvement 09:07 Overcoming Challenges and Putting in Extra Work 10:02 The Importance of a Great Start 11:19 The Difficulty of Finding Coaching and the Need for Patience 13:12 The Benefits of Having a Personal Coach 14:33 Adding New Elements to the Game 15:20 Working on Defense and Optioning 21:57 The Brazilian Style of Coaching and Technique Analysis 23:05 Observing and Analyzing Players Before Making Changes 27:46 Drills for Improving Defense 32:17 Working on Reading and Positioning 36:28 Different Defensive Techniques 38:23 The Complexity of Defense 40:19 The Importance of Technique 43:39 The Value of Fans and Competing Internationally 48:30 The Beach Volleyball Culture in the US 53:41 Moving to Florida or California 58:48 Favorite US Partners 01:03:12 The Importance of Energy in Partnerships 01:05:01 How to Find DJ Klasnic 01:07:50 Closing Remarks

A physician-scientist father shares his heartbreaking story of the death of his daughter who was diagnosed with Tay-Sachs disease and how it motivated him to become the CEO of JScreen to prevent this experience in other families.  Matt Goldstein is a physician-scientist and entrepreneur. He has founded companies, built R&D teams, and led strategy and execution of both pre-clinical research and clinical development. Prior to joining JScreen and Emory University, Matt was a Partner at Related Sciences, a venture creation firm. As an entrepreneur at Third Rock Ventures he spent a decade building and operating Third Rock portfolio companies. He was responsible for building and leading the Immunology program at Tango Therapeutics, the centerpiece of Tango's strategic multi-billion dollar partnership with Gilead Sciences, Inc. He also served as the development head for Tango's lead program which entered the clinic in 1H 2022. Matt was a co-founder of Neon Therapeutics leading Translational Medicine and Early Development through completion of their first clinical study and initial public offering. He is a graduate of Swarthmore College and the MD/PhD program at Stanford University, where he pioneered novel cancer immunotherapies in the lab of Ron Levy, MD. He completed his clinical training in Internal Medicine at Harvard Medical School, Brigham & Women's Hospital. He lives in Boston with his wife, Myra, their second daughter Kaia and son Ezra. His oldest daughter Havi died on January 20th, 2021 of Tay-Sachs disease. A quick update that during the episode Matthew mentioned there are 4,000 genetic counselors in the USA, this number has now surpassed 5,000.   During the episode, Matthew recommends the book Bearing the Unbearable: Love, Loss, and the Heartbreaking Path of Grief by Dr. Joanne Cacciatore.    Check out his wife, Myra's organization, Emotion, which is for grieving individuals to find community and cope with loss.    In our next episode we will chat with Myra about Emotion and her upcoming book, Fifty-Seven Fridays, which consists of memoirs from Matt and Myra, Havi's diagnosis, and how they celebrated her life.    Stay tuned for the next new episode of It Happened To Me! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com. 

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Mahta Mortezavi, a Clinical Director for Drug Discovery and Early Development as part of the Anti-infectives Research Unit at Pfizer, as they discuss her recent paper ‘Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumour necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance.'

Contents Podcast Panelists Additional Resources Transcript   In December 2023, we continued our Place Matters webinar series with our second installment: “Understanding Racism's Impact on Child Development: Working Towards Fairness of Place in the United States.” During the webinar, Stephanie Curenton, PhD, Nathaniel Harnett, PhD, Mavis Sanders, PhD, and Natalie Slopen, ScD, discussed their latest research, exploring how racism gets “under the skin” to impact children's development and how it contributes to unequal access to opportunity in the places where children live, grow, play, and learn. Together, they explored ways to dismantle systemic barriers and work toward solutions that promote healthy child development. The webinar discussion has been adapted for this episode of the Brain Architects podcast.  Panelists Stephanie Curenton, PhD (Moderator)Director, Center on the Ecology of Early Development, Boston University

Our 90th weekly NFT livestream. This week we are joined by Zombie Chains to host a LIVE TOURNAMENT featuring ADA Whale, VivaLaCoin, F35, Hoarder & more! Utilizing smart contracts, we showcase this awesome platform built with the help of the CryptoRaggies team. Come join as we kick off with an 8 player Tournament and even some 1v1's for PRIZES YOU CAN WIN! We'll also be hanging out and answering your questions LIVE

This week, the fallout from the RSN collapse impacts sporting franchises and streaming services alike. Nielsen Ratings Show Notes Amazon Prime Video will start showing ads on January 29th - The Verge Amazon in Talks to Invest in Diamond Sports - WSJ Mariners set to take over Root Sports amid cloudy RSN situation YES, MSG networks partner on venture that could lead to new platform (nypost.com) Sinclair quietly fighting MLB in court over Rob Manfred comments (awfulannouncing.com) Max B/R Sports Offering Will Launch As Paid Add-On Later Than Expected Due To Tech Integration Process ‘Warrior' Canceled At Max; Netflix Picks Up Non-Exclusive Rights To 3 Seasons – Deadline ‘White Lotus' Season 3 Casts Parker Posey, Michelle Monaghan, More – The Hollywood Reporter 'Slow Horses' Renewed for Season 5 at Apple TV+ (EXCLUSIVE) 'American Born Chinese' Canceled After One Season at Disney+ One Piece is Getting an Anime Remake (No, Seriously) 'Wednesday' Spinoff with Fred Armisen as Uncle Fester in Early Development at Netflix ‘Battlestar Galactica': Derek Simonds Set As Showrunner Of Reboot – Deadline 'Minx' Canceled at Starz After Network Rescued Show from Max 'Shining Vale Canceled at Starz, Seasons Will Be Removed From Streaming ‘Beacon 23' Renewed For Season 2 By MGM+ – Deadline The Hunger Games: The Ballad of Songbirds and Snakes Recommendations Saltburn The Holdovers Octopath Traveler AEW: World's End

Synopsis: Sean Bohen, M.D., Ph.D., is the President and CEO of Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women's cancers. We're excited to welcome Sean back to the podcast – he last appeared on episode 130 in late 2022. Sean provides an update on all the exciting things that have happened at Olema since then, including an update on their lead product candidate. Sean reflects on navigating the challenging biotech market environment over the past year, making careful spending decisions, and raising significant capital to extend Olema's runway. He also offers advice to first-time CEOs on building a strong support network to guide company growth. Biography: Dr. Bohen has served as Chief Executive Officer of Olema Oncology and a member of the Board of Directors since September 2020. He is also a non-executive director of Gyroscope Therapeutics, Ltd. and AltruBio, Inc. He has extensive oncology drug development experience, having served as Executive Vice President, Global Medicines Development, and Chief Medical Officer at AstraZeneca PLC. Before that, he held a number of senior leadership roles at Genentech, Inc., including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to Genentech, he was a Clinical Instructor in Oncology at Stanford University School of Medicine; a research associate at the Howard Hughes Medical Institute; and a postdoctoral fellow at the National Cancer Institute (NCI). Dr. Bohen received a B.S. in bacteriology from the University of Wisconsin-Madison, and a Ph.D. in biochemistry and biophysics and an M.D. from the University of California, San Francisco.

Lex chats with Eva Shang, CEO of Legalist - a technology-powered investment firm specialising in alternative assets. Shang discusses her company's strategies in litigation finance, bankruptcy, and government receivables. She explains that Legalist uses technology and data analysis to identify investment opportunities in the legal space. Shang also discusses the challenges and complexities of underwriting litigation cases and the importance of human judgment in the process. She highlights the need for uncorrelated sources of return in the investment landscape and the potential for technology to transform other asset classes. Shang also expresses caution about retail investors entering alternative investment spaces without proper knowledge and understanding of the risks involved. MENTIONED IN THE CONVERSATION Legalist's Website: https://bit.ly/46masHpEva's LinkedIn profile: https://bit.ly/49GENmD Topics: fintech, hedge fund, litigation finance, asset management, alternative investments, AI, artificial intelligence, underwriting, investment Companies: Legalist, Y-Combinator, LexisNexis ABOUT THE FINTECH BLUEPRINT 

If you think that there's something necessary or good about medical licensing, you might want to tune in to this episode. In it, independent journalist Jeremy R Hammond and I demolish some of the myths around medical licensing. You might be surprised by what you hear.Jeremy's articles on "Why Medical Licensing Should be Eliminated" can be found here and here.And here is some of the analysis we referenced:Ronald Hamowy, “The Early Development of Medical Licensing Laws in the United States, 1875-1900”, Journal of Libertarian Studies, 1979, . Sue A. Blevins, “The Medical Monopoly: Protecting Consumers or Limiting Competition?” Cato Institute Policy Analysis, December 15, 1995, . Charles H. Baron, “Licensure of Health Care Professionals: The Consumer's Case for Abolition”, American Journal of Law & Medicine, April 29, 2021, . Jeffrey A. Singer & Richard P. Menger, “The Coronavirus Pandemic Shows the Folly of Medical-Licensing Laws”, National Review, May 29, 2020,

Sonja Bindus, classical pedagogy trainer for the Hillsdale K-12 Education Office, joins host Scot Bertram to discuss how to help preschoolers thrive, her history with Mary Randall Preschool on Hillsdale College's campus, and what experienced teachers can learn from first-time teachers.See omnystudio.com/listener for privacy information.

Today's episode features Aviv Regev, PhD, the Head and Executive VP of Genentech Research and Early Development, and founding co-chair of the Human Cell Atlas. She is joined by Vijay Pande of Bio + Health.Together, Aviv and Vijay talk about how Aviv's love of both abstractions and details led her to biology, how CRISPR really set the field into motion, and how AI could transform the process of biological and medical discovery.